Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsHKSE:02142 -4.65%73 Days Payable is 342.60 as of Dec. 2025, which is 91% below its 10-year median of 3,774.39. GuruFocus rates HKSE:02142 with a GF Score™ of 73/100 and a GF Value™ of HK$7.03 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, HBM Holdings ranks better than 69.09% on this metric.
The historical rank and industry rank for HBM Holdings's Days Payable or its related term are showing as below:
HKSE:02142'
s Days Payable Range Over the Past 10 Years
Min: 274.6 Med: 3774.39 Max: 67419.43
Current: 274.6
During the past 8 years, HBM Holdings's highest Days Payable was 67419.43. The lowest was 274.60. And the median was 3774.39.
HKSE:02142's Days Payable is ranked better than 69.09% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs HKSE:02142: 274.60
HBM Holdings's Days Payable
increased
from Dec. 2024 (294.71) to Dec. 2025 (342.60).
It may suggest that HBM Holdingsdelayed paying its suppliers.
HBM Holdings Days Payable Related Terms
HBM Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for HBM Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02142 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, HBM Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where HBM Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
HBM Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (HKSE:02142) has a Days Payable of 342.60 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HBM Holdings and its competitors. This is 91% below median its historical median of 3,774.39. Over the past decade, HBM Holdings' Days Payable has ranged from 274.60 to 67,419.43. According to the industry distribution chart, HBM Holdings ranks #217 out of 702 companies in the Biotechnology industry, placing it in the top 30.9%.
Is HBM Holdings' Days Payable too high?
HBM Holdings' current Days Payable of 342.60 is 91% below median its 10-year median of 3,774.39. Over the past 10 years, this metric has ranged from a low of 274.60 to a high of 67,419.43. The Biotechnology industry median Days Payable is 113.10. HBM Holdings' value of 342.60 is 202.9% above this industry median. Based on the distribution chart, HBM Holdings ranks #217 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HBM Holdings has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #217 out of 702 companies for Days Payable. This puts HBM Holdings in the upper half of its industry. The industry median Days Payable is 113.10. HBM Holdings' value of 342.60 is 202.9% above this benchmark. Historically, HBM Holdings' own Days Payable has ranged from 274.60 to 67,419.43 over the past decade. While the company's 10-year median is 3,774.39 vs. the industry median of 113.10, HBM Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current Days Payable of 342.60 is 202.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current Days Payable is 342.60, which is 91% below median its own 10-year median of 3,774.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (HKSE:02142) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$7.03, compared to a current price of HK$11.69 — trading 66.3% above its estimated fair value. The current Days Payable is 342.60, which is 91% below median its 10-year median of 3,774.39 and 202.9% above the Biotechnology industry median of 113.10. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For HBM Holdings (HKSE:02142), the current Days Payable is 342.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (HKSE:02142) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of HK$11.69 is trading 66.3% above its estimated GF Value™ of HK$7.03.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:02142:
Days Payable: 342.60 (91% below median its 10-year median of 3,774.39)
GF Value™: HK$7.03 vs. price of HK$11.69 (66.3% above fair value)
Industry Position: 202.9% above the Biotechnology median (#217 of 702)
No single metric tells the full story. See the HKSE:02142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score
Get the complete analysis for HKSE:02142
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02142 has been successfully added to your 
